211At-MABG for Neuroendocrine Tumors

This trial tests a new treatment called 211At-MABG, a type of targeted radiotherapy, for individuals with certain advanced neuroendocrine tumors unresponsive to traditional treatments. Researchers aim to assess the safety and effectiveness of 211At-MABG by experimenting with different dose levels. The trial seeks participants whose tumors absorb a specific tracer, which aids in tumor detection on imaging tests, and who have not found success with other available treatments. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

Previous studies have explored 211At-MABG in various contexts, revealing some potential benefits. Research suggests that it might offer survival benefits for glioblastoma, a type of brain cancer. However, this trial primarily focuses on its safety.

For neuroblastoma, a cancer originating in certain early nerve cells, studies have assessed the safety and patient tolerance of 211At-MABG. Although detailed safety data from these studies is limited, the continuation of clinical trials suggests it has been reasonably well-tolerated so far.

Like many treatments, 211At-MABG may have side effects, but specific details are not clearly provided in the sources. As this is an early-phase trial, the main goal is to assess safety and determine safe dosage levels, meaning the treatment is still under careful study to understand its safety.

Unlike the standard treatments for neuroendocrine tumors, which often include surgery, chemotherapy, and radiation, the investigational treatment 211At-MABG introduces a novel approach by using astatine-211 as an active ingredient. This treatment is unique because it delivers targeted radiation directly to tumor cells through a process called radioimmunotherapy. Researchers are excited about 211At-MABG because it has the potential to more precisely target cancer cells, potentially reducing harm to healthy tissue and resulting in fewer side effects compared to traditional radiation therapy. Additionally, the fractionated dosing strategy allows for a controlled delivery of the treatment, which could enhance its effectiveness and tolerability.

Research has shown that 211At-MABG might help treat neuroendocrine tumors by delivering targeted radiation directly to cancer cells. This treatment uses a type of radiation known for effectively killing cancer cells while mostly sparing healthy tissue. Laboratory studies have demonstrated that 211At-MABG can successfully locate and destroy tumor cells in models of neuroblastoma, a cancer often found in the adrenal glands. Although human trial data remains limited, early results in similar conditions appear promising for both effectiveness and safety. This trial will explore different dose levels of 211At-MABG, offering hope for patients with advanced neuroendocrine tumors unresponsive to standard treatments.⁶⁷⁸⁹¹⁰